bioAffinity Technologies, Inc. has announced that it will present new data at the CHEST 2026 conference, a significant event hosted by the American College of Chest Physicians. This presentation will focus on the company's investigational sputum-based tests aimed at characterizing lung inflammation and detecting multiple protein biomarkers associated with conditions like asthma and chronic obstructive pulmonary disease (COPD).
This announcement is crucial for bioAffinity Technologies as it seeks to advance its research and development efforts in the field of respiratory health. The company's innovative approach could potentially lead to new diagnostic tools that enhance the understanding and treatment of lung diseases.
Background
bioAffinity Technologies, Inc. is a Delaware corporation engaged in commercial physical and biological research, as indicated by its SIC code 8731. The company is publicly traded on the Nasdaq under the ticker symbols BIAF and BIAFW. Recently, bioAffinity has been active in filing various reports, including an 8-K on October 13, 2026, detailing this latest announcement.
What the Filing Says
According to the SEC filing (accession number 0001493152-26-046755), the company stated, "On October 13, 2026, bioAffinity Technologies, Inc. issued a press release announcing that it will present new data at CHEST 2026... These sputum-based tests are investigational, have not been validated, are not cleared or approved by the U.S. Food and Drug Administration, and are not currently available for clinical or diagnostic use." This highlights the experimental nature of the tests and the ongoing research required before they can be utilized in clinical settings.
Impact
The announcement may significantly impact healthcare providers, researchers, and patients dealing with asthma and COPD. If successful, the tests could provide new insights into lung health and improve therapeutic strategies. The findings presented at CHEST 2026 could also influence the direction of future research and development within the industry.
What's Next
Following this announcement, bioAffinity Technologies is expected to continue its research and development efforts. However, the filing does not specify what immediate actions will follow the presentation at the CHEST 2026 conference.